Latest News and Press Releases
Want to stay updated on the latest news?
-
PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
-
PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
-
PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
-
Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24 hours of infectious SARS-CoV-2 challenge with absence of...
-
PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray...
-
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
-
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
-
Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technologyOyster Point Pharma plans to discuss the potential for...
-
Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK)Preclinical study results from a 42-day...
-
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDAOLYMPIA Phase 2 Study on Track,...